

Research

## Genome-wide association with select biomarker traits in the Framingham Heart Study

Emelia J Benjamin<sup>\*1,2,3,4</sup>, Josée Dupuis<sup>1,4</sup>, Martin G Larson<sup>1,5</sup>, Kathryn L Lunetta<sup>1,4</sup>, Sarah L Booth<sup>6</sup>, Diddahally R Govindaraju<sup>1,2</sup>, Sekar Kathiresan<sup>7,8</sup>, John F Keaney Jr<sup>2,3</sup>, Michelle J Keyes<sup>1,5</sup>, Jing-Ping Lin<sup>10</sup>, James B Meigs<sup>9</sup>, Sander J Robins<sup>1,2</sup>, Jian Rong<sup>1,4</sup>, Renate Schnabel<sup>1,2</sup>, Joseph A Vita<sup>2,3</sup>, Thomas J Wang<sup>8</sup>, Peter WF Wilson<sup>11</sup>, Philip A Wolf<sup>1,2</sup> and Ramachandran S Vasan<sup>1,2,3</sup>

Address: <sup>1</sup>The National Heart Lung and Blood Institute's Framingham Heart Study, Framingham, MA, USA, <sup>2</sup>School of Medicine, Boston University, Boston, MA, USA, <sup>3</sup>Whitaker Cardiovascular Institute, Boston University, Boston, MA, USA, <sup>4</sup>School of Public Health, Boston University, Boston, MA, USA, <sup>5</sup>Department of Mathematics and Statistics, Boston, MA, USA, <sup>6</sup>Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA, <sup>7</sup>Broad Institute of Massachusetts Institute of Technology, Cambridge, MA, USA, <sup>8</sup>Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston, MA, USA, <sup>9</sup>Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Harvard University, Boston, MA, USA, <sup>10</sup>Office of Biostatistics Research, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA and <sup>11</sup>Emory School of Medicine, Atlanta, GA, USA

Email: Emelia J Benjamin\* - [emelia@bu.edu](mailto:emelia@bu.edu); Josée Dupuis - [dupuis@bu.edu](mailto:dupuis@bu.edu); Martin G Larson - [mlarson@bu.edu](mailto:mlarson@bu.edu); Kathryn L Lunetta - [klunetta@bu.edu](mailto:klunetta@bu.edu); Sarah L Booth - [sarah.booth@tufts.edu](mailto:sarah.booth@tufts.edu); Diddahally R Govindaraju - [drgraju@bu.edu](mailto:drgraju@bu.edu); Sekar Kathiresan - [SKATHIRESAN1@PARTNERS.ORG](mailto:SKATHIRESAN1@PARTNERS.ORG); John F Keaney - [jkeaney@bu.edu](mailto:jkeaney@bu.edu); Michelle J Keyes - [mjkeyes@bu.edu](mailto:mjkeyes@bu.edu); Jing-Ping Lin - [linj@nhlbi.nih.gov](mailto:linj@nhlbi.nih.gov); James B Meigs - [jmeigs@partners.org](mailto:jmeigs@partners.org); Sander J Robins - [sjrobbins@bu.edu](mailto:sjrobbins@bu.edu); Jian Rong - [jrong@bu.edu](mailto:jrong@bu.edu); Renate Schnabel - [schnabel@bu.edu](mailto:schnabel@bu.edu); Joseph A Vita - [jvita@bu.edu](mailto:jvita@bu.edu); Thomas J Wang - [tjwang@partners.org](mailto:tjwang@partners.org); Peter WF Wilson - [pwwilso@emory.edu](mailto:pwwilso@emory.edu); Philip A Wolf - [pawolf@bu.edu](mailto:pawolf@bu.edu); Ramachandran S Vasan - [vasan@bu.edu](mailto:vasan@bu.edu)

\* Corresponding author

Published: 19 September 2007

*BMC Medical Genetics* 2007, **8**(Suppl 1):S11 doi:10.1186/1471-2350-8-S1-S11

This article is available from: <http://www.biomedcentral.com/1471-2350/8/S1/S11>

© 2007 Benjamin et al; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Systemic biomarkers provide insights into disease pathogenesis, diagnosis, and risk stratification. Many systemic biomarker concentrations are heritable phenotypes. Genome-wide association studies (GWAS) provide mechanisms to investigate the genetic contributions to biomarker variability unconstrained by current knowledge of physiological relations.

**Methods:** We examined the association of Affymetrix 100K GeneChip single nucleotide polymorphisms (SNPs) to 22 systemic biomarker concentrations in 4 biological domains: inflammation/oxidative stress; natriuretic peptides; liver function; and vitamins. Related members of the Framingham Offspring cohort ( $n = 1012$ ; mean age  $59 \pm 10$  years, 51% women) had both phenotype and genotype data (minimum-maximum per phenotype  $n = 507$ – $1008$ ). We used Generalized Estimating Equations (GEE), Family Based Association Tests (FBAT) and variance components linkage to relate SNPs to multivariable-adjusted biomarker residuals. Autosomal SNPs ( $n = 70,987$ ) meeting the following criteria were studied: minor allele frequency  $\geq 10\%$ , call rate  $\geq 80\%$  and Hardy-Weinberg equilibrium  $p \geq 0.001$ .

**Results:** With **GEE**, 58 SNPs had  $p < 10^{-6}$ : the top SNPs were rs2494250 ( $p = 1.00 \times 10^{-14}$ ) and rs4128725 ( $p = 3.68 \times 10^{-12}$ ) for monocyte chemoattractant protein-1 (MCP1), and rs2794520 ( $p = 2.83 \times 10^{-8}$ ) and rs2808629 ( $p = 3.19 \times 10^{-8}$ ) for C-reactive protein (CRP) averaged from 3 examinations (over about 20 years). With **FBAT**, 11 SNPs had

$p < 10^{-6}$ : the top SNPs were the same for MCP1 (rs4128725,  $p = 3.28 \times 10^{-8}$ , and rs2494250,  $p = 3.55 \times 10^{-8}$ ), and also included B-type natriuretic peptide (rs437021,  $p = 1.01 \times 10^{-6}$ ) and Vitamin K percent undercarboxylated osteocalcin (rs2052028,  $p = 1.07 \times 10^{-6}$ ). The peak **LOD** (logarithm of the odds) scores were for MCP1 (4.38, chromosome 1) and CRP (3.28, chromosome 1; previously described) concentrations; of note the 1.5 support interval included the MCP1 and CRP SNPs reported above (GEE model). Previous candidate SNP associations with circulating CRP concentrations were replicated at  $p < 0.05$ ; the SNPs rs2794520 and rs2808629 are in linkage disequilibrium with previously reported SNPs. GEE, FBAT and linkage results are posted at <http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007>.

**Conclusion:** The Framingham GWAS represents a resource to describe potentially novel genetic influences on systemic biomarker variability. The newly described associations will need to be replicated in other studies.

## Background

There is intense clinical and research interest in blood and urinary biomarkers to diagnose disease, to risk stratify individuals for prognosis and potential intervention, and to provide insights into disease pathogenesis [1]. Hence, it has been proposed that biomarkers may prove useful in the goal of developing what has been referred to as "predictive, preemptive, personalized medicine" [2].

In the present analysis, we examined biomarkers involving four biological systems: inflammation, natriuretic peptides, hepatic function, and vitamins. Circulating inflammatory, natriuretic peptides [3-5], hepatic function [6,7] and vitamin [8] biomarker concentrations have been linked to increased risk of cardiovascular disease and mortality. For instance, the inflammatory marker C-reactive protein (CRP) predicts incident stroke [9], coronary heart disease [10-12], and all-cause mortality [13].

Because of their prognostic importance, there has been interest in understanding the environmental and genetic factors contributing to interindividual variability in systemic biomarker concentrations. Prior reports support the heritability of systemic biomarker concentrations reflecting inflammatory processes [14,15], natriuretic peptides activation [16], hepatic function [17,18], and vitamin metabolism [19]. The majority of prior studies examining the genetic contribution to biomarker concentrations have examined genetic linkage or variation in selected candidate genes. Although there have been some successes with both approaches [20], the specific genes contributing to variability of most circulating biomarkers are incompletely understood. We examined the relation of single nucleotide polymorphisms (SNPs) on the Affymetrix 100K chip to variation in systemic biomarker concentrations. The GWAS approach has the advantage that it is not constrained by known physiologic associations.

## Materials and methods

### Study sample

The biomarkers were assessed in the Framingham Offspring sample, which is described in the Framingham

100K Overview [21]. Briefly, the Framingham Offspring were recruited in 1971-1974 from the children (and children's spouses) of the Framingham Original Cohort [22]. The examinations and the number of participants in which the biomarkers were assessed vary by analyte, as noted in Table 1.

### Phenotype definitions and methods

Biomarkers were measured on morning specimens after an overnight fast (typically 10 hours) between 7:30 and 9:00 am. EDTA and citrated blood collection tubes are centrifuged in a refrigerated centrifuge immediately after venipuncture. Serum blood collection tubes sit for 30 minutes after venipuncture to allow for complete clotting. Specimens are processed immediately after centrifugation. Blood samples were centrifuged and frozen at  $-20^{\circ}$  (examination 2 through 4) and  $-80^{\circ}$  (examinations 5 through 7). The measurement of the inflammatory markers is detailed in the inflammatory marker manual at the National Center for Biotechnology Information <http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007>.

**Inflammatory biomarkers** (except CRP) were measured in duplicate with commercially available ELISA kits: R&D Systems (intercellular adhesion molecule-1, interleukin-6, monocyte chemoattractant-1 [MCP1], P-selectin, tumor necrosis factor receptor 2, high sensitivity tumor necrosis factor- $\alpha$ ), Bender MedSystems (CD40 ligand), Oxis (myeloperoxidase), and BIOMEDICA (osteoprotegerin). High-sensitivity CRP was measured in 2002 and 2004 on examination cycle 2, 6 and 7 specimens with a Dade Behring nephelometer; the less sensitive Hemagen assay was used in 1998 for examination cycle 5 specimens. **Natriuretic peptides** were measured by Shionogi using a noncompetitive high sensitivity immunoradiometric assay [23]. **Liver function tests** were measured at examination cycle 2 by Quest Diagnostics (previously METPATH) with a variety of methods:  $\gamma$ -glutamyl aminotransferase was measured with spectrophotometry [7], bilirubin was measured by the colorimetric method (Dow Bilirubin Kit) [24,25]; alkaline phosphatase was meas-

**Table 1: Types of traits phenotype master trait table, exam cycle, numbers of participants in family plates with phenotype**

Phenotype	Acronym	Trait N = 27*	Subject N	Offspring Exam	Adjustment* Multivariable model
<b>Inflammation/Oxidative Stress</b>					
CD40 Ligand, serum & plasma	CD40L	2	998	7	Age, sex, smoking, systolic and diastolic blood pressure, hypertension treatment, body mass index, waist circumference, Total/HDL cholesterol, triglyceride, lipid lowering medication, glucose, diabetes, aspirin, hormone replacement therapy and prevalent cardiovascular disease
C-reactive protein	CRP	5	980-1008	2, 5, 6, 7; Average: 2, 6, 7	
Intercellular adhesion molecule-1	ICAM1	1	1006	7	
Interleukin-6	IL6	1	1006		
Urinary isoprostanes/creatinine	IsoCrUrine	1	828		
Monocyte chemoattractant protein-1	MCPI	1	989		
Myeloperoxidase	MPO	1	974		
Osteoprotegerin	OPG	1	1005		
P-selectin	Pselectin	1	1007		
Tumor necrosis factor alpha	TNFA	1	753		
Tumor necrosis factor receptor-2	TNFR2	1	980		
<b>Natriuretic Peptides</b>					
N-terminal pro-atrial natriuretic peptide	ANP	1	938	6	Age, sex, BMI, SBP, HTN Rx, LDL Total/HDL, diabetes, LV mass, LA size, CVD
B-type natriuretic peptide	BNP	1	938		
<b>Liver Function</b>					
Bilirubin	Bili	1	910	2	Age, sex, BMI, HDL, HTN, diabetes, serum total protein, alcohol intake, TG, & smoking
Aspartate aminotransferase **	AST	1	904		
Alanine aminotransferase	ALT	1	904		
Alkaline phosphatase	AlkPhos	1	904		
Gamma-glutamyl transferase	GGT	1	896		
<b>Vitamins</b>					
Vitamin K plasma phyloquinone	VitKPhylloq	1	518	6/7†	Age, sex, SBP, DBP, BMI, waist, total/HDL, smoking, glucose, TG, diabetes, HTN Rx, lipid lowering Rx, hormone replacement Rx, asthma Rx, alcohol use, prevalent CVD
Vitamin K percentage of undercarboxylated osteocalcin	VitKPucOC	1	504		
Vitamin D plasma 25(OH)-D	VitD25OH	1	517		

\*Each trait had 2 adjustment schemes web posted: age- and sex-adjusted, and multivariable-adjusted at <http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007>. GEE and FBAT traits are web displayed pha001115 through pha001218; Linkage traits are located from pha002301 through pha002352. In the present manuscript we examine the multivariable-adjusted trait, which we count as 1 trait. Note: biomarkers were natural log transformed due to skewed distribution; \*\*normalized deviates. †Vitamin measurements straddled exams 6 & 7, covariates from same exam biomarker assayed. SBP, DBP = systolic and diastolic blood pressure, HTN Rx = hypertension treatment, BMI = body mass index, TC/HDL = total/high density lipoprotein cholesterol; TG = triglyceride, HRT = hormone replacement therapy, Rx = medication therapy, CVD = cardiovascular disease; LDL = low density lipoprotein; LV mass = left ventricular mass; LA size = left atrial size; Atrial natriuretic peptide = N-terminal pro-atrial natriuretic peptide.

ured with the kinetic method [26,27]; aspartate aminotransferase and alanine aminotransferase were measured using the kinetic method with Beckman Liquid-Stat Reagent Kit [28]. Vitamin K status was measured as phyloquinone concentrations with reverse phase high-performance liquid chromatography [29], and percentage of undercarboxylated osteocalcin was measured by radio-immunoassay [30,31], Vitamin D status was measured as

25(OH)D concentrations by using RIA (DiaSorin, Stillwater MN).

Plasma samples were used for natriuretic peptides, vitamin K phyloquinone, vitamin D, and some inflammatory markers including CD40 ligand, osteoprotegerin, P-selectin, tumor necrosis factor receptor 2, and tumor necrosis factor- $\alpha$ . Serum samples were analyzed for liver

function, vitamin K, % undercarboxylated osteocalcin, and other inflammatory markers including CRP, interleukin-6, soluble intracellular adhesion molecule-1, MCP1, and myeloperoxidase concentrations. The reproducibility of the biomarkers was good; the intra-assay coefficients of variation were CD40 ligand 4.4%, interleukin-6 3.1%, intercellular adhesion molecule-1 3.1%, MCP1 4.1%, myeloperoxidase 3.0%, osteoprotegerin 3.7%, P-selectin 3.0%, tumor necrosis factor- $\alpha$  8.8%, and tumor necrosis factor receptor-2 2.3%; the inter-assay coefficients of variation were brain natriuretic peptide 12.2%, n-terminal-atrial natriuretic peptide 12.7%. The Kappa statistic for 146 CRP samples run in duplicate was 0.95 [32]. Coefficients of variation for aspartate aminotransferase and alanine aminotransferase, respectively, were 10.7 and 8.3%. The coefficients of variation for low and high Vitamin K plasma phylloquinone concentrations were 15.2 and 10.9% respectively on control specimens. For low, medium and high osteocalcin concentrations used to determine Vitamin K percentage of undercarboxylated osteocalcin, the coefficients of variation were 22.3, 12.8, and 7.8%, respectively. For Vitamin D, the coefficients of variation were 8.5% and 13.2%, respectively.

#### Genotyping methods

Details of the genotyping methods are available in the Framingham Heart Study 100K Overview [21]. Framingham staff extracted genomic DNA with a Qiagen Blood and Cell Culture Maxi Kit from immortalized lymphoblasts. Briefly, SNPs on the Affymetrix 100K chip were genotyped ( $n = 112,990$  autosomal SNPs) in a sample of family members of the Original and Offspring cohorts of the Framingham Heart Study [33]. SNPs were excluded for the following reasons: minor allele frequency  $<10\%$   $n = 38062$ ; call rate  $<80\%$   $n = 2346$ ; Hardy-Weinberg equilibrium  $p$ -value  $<0.001$   $n = 1595$ , leaving 70,987 SNPs available for analysis.

#### Statistical analysis methods

We created standardized multivariable-adjusted natural log transformed biomarker residuals adjusted for the covariates listed in Table 1. The CRP average residuals were constructed as follows: (1) create age- and sex-adjusted or multivariable-adjusted residual at each of exams 2, 6 and 7; (2) take average of the residuals across exams; (3) the residual was excluded if there were not at least 2 exams for its calculation. In some instances we performed additional transformation (e.g. Winsorized models). Tobit models were used to generate residuals for the natriuretic peptides, because 2% of N-ANP levels and 30% of BNP levels were below the respective assay detection limits. Association and linkage results examining age- and sex-adjusted residuals are posted at the web site. As described in the Overview [21], we examined generalized estimating

equations (GEE) and family based association testing (FBAT), assuming an additive genetic effect, to account for correlation among related individuals within nuclear families. We also used Merlin software [34] (splitting the largest families) to compute exact identity by descent linkage, with variance component analysis in SOLAR using 11,200 SNPs and short tandem repeats [35]. Traits with extreme values, as defined by 4 standard deviations away from the mean, were Winsorized at 4.0 in secondary linkage analyses to determine the sensitivity of the logarithm of the odds (LOD) score to the presence of outlier values.

#### Results

Twenty-two biomarker traits (plus 4 additional CRP traits) were analyzed in 1012 Offspring participants, on log-transformed multivariable-adjusted residuals as outlined in Table 1 (minimum-maximum per phenotype  $n = 507$ – $1008$ ). The phenotypes were collected at various Framingham Offspring examinations from cycles 2 to 7. At examination cycles 2 and 7 the mean age of the participants with both phenotype and genotype data was  $41 \pm 10$  and  $59 \pm 10$  years, and 51.2% and 51.1% were women, respectively. For details of biomarker phenotype-genotype association refer to <http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?id=phs000007>.

There were 58 SNPs associated with biomarker concentrations with a  $p < 10^{-6}$  by GEE. The 25 most statistically significant GEE associations sorted by  $p$ -value, listed with their corresponding FBAT  $p$ -value are shown in Table 2a. MCP1 concentrations were associated with rs2494250 ( $p = 1 * 10^{-14}$ ) and rs4128725 ( $p = 3.68 * 10^{-12}$ ), both on chromosome 1, near the *FCER1A* and the *OR10J1* genes, respectively. CRP concentrations averaged over 3 examinations (about 20 years) were associated with rs2794520 ( $p = 2.83 * 10^{-8}$ ) and rs2808629 ( $p = 3.19 * 10^{-8}$ ).

We estimated the amount of variability in biomarker concentrations explained by the 4 most statistically significant SNPs in the GEE model using a pseudo measure of  $R^2$  based on log-likelihood estimates [36]. The two most statistically significant GEE SNPs explained about 7% and 4% of the variability in MCP1 concentrations ( $R^2 = 0.070$  for rs2494250 and  $R^2 = 0.043$  for rs4128725); for CRP concentrations averaged over examinations 2, 6, and 7 the two most statistically significant GEE SNPs explained 2.3% of the variability [ $R^2 = 0.023$  for rs2794520 and rs2808629] [36]. We also examined the linkage disequilibrium between the most statistically significant GEE SNPs: rs2494250 and rs4128725 had a  $D' = 0.724$  and an  $r^2 = 0.196$ , whereas rs2794520 and rs2808629 served as perfect proxies for each other ( $D' = 1$ ;  $r^2 = 1$ ).

With FBAT, 11 SNPs were associated with biomarker concentrations with a  $p < 10^{-6}$ . The two most statistically sig-

**Table 2: Top genetic associations with biomarkers based on the lowest p value for GEE test (2a), FBAT (2b), and Linkage (2c)**

<b>2a. Top 25 associations with biomarkers based on the lowest p value of the GEE test</b>						
Trait	SNP rs ID*	Chr	Physical location (bp)	GEE P-value	FBAT P-value	IN/NEAR gene
Monocyte chemoattractant protein-1	rs2494250	1	156091324	<b>1.0*10<sup>-14</sup></b>	3.5*10 <sup>-8</sup>	FCER1A, OR10J3
Monocyte chemoattractant protein-1	rs4128725	1	156219032	<b>3.7*10<sup>-12</sup></b>	3.3*10 <sup>-8</sup>	OR10J1
C-reactive protein average exams 2,6,7	rs2794520	1	156491889	<b>2.8*10<sup>-8</sup></b>	4.3*10 <sup>-5</sup>	CRP
C-reactive protein average exams 2,6,7	rs2808629	1	156489869	<b>3.2*10<sup>-8</sup></b>	4.8*10 <sup>-5</sup>	CRP
C-reactive protein exam 6	rs2794520	1	156491889	<b>1.3*10<sup>-7</sup></b>	3.9*10 <sup>-4</sup>	CRP
C-reactive protein exam 6	rs2808629	1	156489869	<b>1.4*10<sup>-7</sup></b>	4.3*10 <sup>-4</sup>	CRP
Tumor necrosis factor alpha	rs7552393	1	83966572	<b>5.1*10<sup>-7</sup></b>	0.63	
C-reactive protein exam 6	rs746961	19	35791730	<b>7.5*10<sup>-7</sup></b>	0.03	ZNF536
Bilirubin	rs17532515	4	141745043	<b>1.0*10<sup>-6</sup></b>	9.2*10 <sup>-6</sup>	CLGN, ELMOD2
Alanine aminotransferase	rs1998303	9	82644535	<b>1.1*10<sup>-6</sup></b>	0.005	
Monocyte chemoattractant protein-1	rs10489849	1	156009838	<b>1.1*10<sup>-6</sup></b>	0.10	IGSF4B
Alkaline phosphatase	rs10518765	15	52467924	<b>1.1*10<sup>-6</sup></b>	1.7*10 <sup>-4</sup>	
Vitamin K plasma phyloquinone	rs2387326	10	129823446	<b>1.1*10<sup>-6</sup></b>	0.02	PTPRE, MKI67
C-reactive protein average exams 2,6,7	rs1119582	5	125270919	<b>1.2*10<sup>-6</sup></b>	4.2*10 <sup>-4</sup>	
Vitamin D plasma 25(OH)-D	rs10485165	6	89169536	<b>1.4*10<sup>-6</sup></b>	0.003	
Atrial natriuretic peptide exam 6	rs1417352	6	107005919	<b>1.8*10<sup>-6</sup></b>	0.009	
C-reactive protein exam 2	rs583012	10	54964880	<b>1.9*10<sup>-6</sup></b>	0.09	
Atrial natriuretic peptide exam 6	rs1486139	7	46048968	<b>2.0*10<sup>-6</sup></b>	0.04	
Atrial natriuretic peptide exam 6	rs1486140	7	46048877	<b>2.2*10<sup>-6</sup></b>	0.06	
Alanine aminotransferase exam 2	rs10492681	13	39705483	<b>2.2*10<sup>-6</sup></b>	9.9*10 <sup>-5</sup>	
Vitamin D plasma 25(OH)-D	rs10507577	13	52866092	<b>2.6*10<sup>-6</sup></b>	0.004	
Atrial natriuretic peptide exam 6	rs1079596	11	112801829	<b>2.6*10<sup>-6</sup></b>	0.03	DRD2
Monocyte chemoattractant protein-1	rs1474747	1	155961586	<b>2.8*10<sup>-6</sup></b>	8.7*10 <sup>-4</sup>	IGSF4B
CD40 Ligand serum	rs7778619	7	9923216	<b>3.0*10<sup>-6</sup></b>	0.19	
CD40 Ligand serum	rs8005745	14	76473583	<b>3.5*10<sup>-6</sup></b>	0.01	

  

<b>2b. Top 25 associations with biomarkers based on the lowest p value of the FBAT test</b>						
Trait	SNP rs ID*	Chr	Physical location (bp)	GEE P-value	FBAT P-value	IN/NEAR gene
Monocyte chemoattractant protein-1	rs4128725	1	156219032	3.7*10 <sup>-12</sup>	<b>3.3*10<sup>-8</sup></b>	OR10J1
Monocyte chemoattractant protein-1	rs2494250	1	156091324	1.0*10 <sup>-14</sup>	<b>3.5*10<sup>-8</sup></b>	FCER1A, OR10J3
B-type natriuretic peptide	rs437021	1	61450291	1.5*10 <sup>-4</sup>	<b>1.0*10<sup>-6</sup></b>	NFIA
Vitamin K % undercarboxylated osteocalcin	rs2052028	7	15789103	5.2*10 <sup>-6</sup>	<b>1.1*10<sup>-6</sup></b>	
CD40 Ligand plasma	rs2372184	3	65673194	0.003	<b>2.5*10<sup>-6</sup></b>	MAG11
Urinary isoprostanes/creatinine	rs717145	20	15826091	0.003	<b>5.0*10<sup>-6</sup></b>	C20orf133
CD40 Ligand serum	rs4664604	2	153398916	0.01	<b>8.4*10<sup>-6</sup></b>	ARL6IP6
CD40 Ligand serum	rs9288125	2	153348619	0.01	<b>9.1*10<sup>-6</sup></b>	FMNL2, ARL6IP6
C-reactive protein exam 7	rs1363258	5	103297593	0.02	<b>9.2*10<sup>-6</sup></b>	

**Table 2: Top genetic associations with biomarkers based on the lowest p value for GEE test (2a), FBAT (2b), and Linkage (2c)**

Bilirubin	rs17532515	4	141745043	1.0*10 <sup>-6</sup>	<b>9.2*10<sup>-6</sup></b>	CLGN, ELMOD2
Osteoprotegerin	rs496269	6	79457094	0.03	<b>9.4*10<sup>-6</sup></b>	
C-reactive protein average 2,6,7	rs1363258	5	103297593	0.009	<b>1.3*10<sup>-5</sup></b>	
CD40 Ligand serum	rs303939	13	71269472	0.008	<b>1.3*10<sup>-5</sup></b>	DACHI
Myeloperoxidase	rs10501981	11	100880825	1.1*10 <sup>-5</sup>	<b>1.4*10<sup>-5</sup></b>	TRPC6
Urinary isoprostanes/creatinine	rs1461549	14	24782140	0.26	<b>1.5*10<sup>-5</sup></b>	
Tumor necrosis factor alpha	rs2353803	7	11060282	0.03	<b>1.5*10<sup>-5</sup></b>	
Intercellular adhesion molecule-1	rs3849944	9	27550594	5.3*10 <sup>-6</sup>	<b>1.5*10<sup>-5</sup></b>	C9orf72
CD40 Ligand serum	rs1986743	2	153412407	0.01	<b>1.6*10<sup>-5</sup></b>	ARL6IP6
Gamma-glutamyl transferase	rs962976	12	67006894	0.002	<b>1.6*10<sup>-5</sup></b>	MDM1
C-reactive protein average 2,6,7	rs2421608	2	117013763	0.02	<b>1.8*10<sup>-5</sup></b>	
C-reactive protein exam 2	rs642245	11	86067184	0.03	<b>1.9*10<sup>-5</sup></b>	ME3
Tumor necrosis factor receptor-2	rs248328	5	179309691	0.59	<b>1.9*10<sup>-5</sup></b>	TBC1D9B, RNF130
C-reactive protein exam 7	rs2390582	1	90655928	0.07	<b>2.0*10<sup>-5</sup></b>	
Osteoprotegerin	rs9352609	6	79442188	0.04	<b>2.0*10<sup>-5</sup></b>	
Intercellular adhesion molecule-1	rs744511	14	39166736	3.2*10 <sup>-4</sup>	<b>2.1*10<sup>-5</sup></b>	

**2c. Magnitude and Location of Peak LOD scores > 2.5 for regions in the Biomarker Phenotype Group**

Trait	Exam	Chr	Physical location (bp)	Maximum LOD	LOD-1.5 Interval	LOD+1.5 Interval	Maximum LOD WIN*
Monocyte chemoattractant protein-1	7	1	159093573	4.96	154908901	159751221	4.38
Monocyte chemoattractant protein-1	7	10	129553148	4.03	128294406	130084334	3.23
C-reactive protein	5	1	154745847	3.53	153213133	156567571	3.28
Monocyte chemoattractant protein-1	7	17	13630703	3.33	10874193	16776778	2.54
Intercellular adhesion molecule-1	7	1	203535232	2.95	202207846	215367881	2.93
Monocyte chemoattractant protein-1	7	7	92544810	2.94	88727093	105546050	2.01
Tumor necrosis factor receptor 2	7	1	54001041	2.92	43070922	60590679	2.95
Gamma-glutamyl transferase	2	3	26424584	2.89	24621158	27418642	2.96
B-type natriuretic peptide	6	12	4140574	2.77	132045	8137669	No outliers
Gamma-glutamyl transferase	2	10	129553148	2.67	120112006	132560638	2.79
Vitamin D plasma 25(OH)-D	6/7	8	140624328	2.67	138952328	146039126	2.68
B-type natriuretic peptide	6	19	34016706	2.59	13425865	43186344	No outliers
Myeloperoxidase	7	19	11295505	2.56	3026853	16489850	2.56
Alkaline phosphatase	2	6	170538204	WIN	162441307	170788550	2.55
Osteoprotegerin	7	13	75274475	2.52	71928655	81228082	2.95

bp = base pair; Chr = chromosome; WIN = Winsorized.  
 dbSNP positions are from NCBI Build 35 (hg17);  
 LD between rs2494250 and rs4128725 (top MCP1 SNPs): D' = 0.724 and r squared = 0.196.  
 LD between rs2794520 and rs2808629 (top CRP SNPs): D' = 1.0 and r squared = 1.0.  
 \*Winsorized LOD scores were run for this manuscript, and are not displayed on the web.

**Table 3: Combined phenotypes**

Trait	SNP rs ID	Chr	Physical location (bp)	GEE P-value	FBAT P-value	IN/NEAR gene
<b>3a. SNPs significant for 3 correlated phenotypes at exam 7 by either GEE or FBAT at p &lt; 0.01</b>						
<b>Interleukin-6, C-reactive protein and Fibrinogen</b>	rs10511884	9	31668988	5.7*10 <sup>-5</sup>	0.0065	
	rs1887027	10	6153788	2.6*10 <sup>-4</sup>	0.19	IL2RA, RBM17
	rs2831617	21	28481515	6.2*10 <sup>-4</sup>	0.0027	
	rs2831620	21	28481869	6.4*10 <sup>-4</sup>	0.0022	
	rs2831618	21	28481749	6.4*10 <sup>-4</sup>	0.0020	
	rs2044401	9	31659518	6.6*10 <sup>-4</sup>	0.12	
	rs1457590	3	21530978	0.0019	0.16	ZNF659
	rs6848323	4	113286305	0.0022	0.14	
	rs3110134	8	60260538	0.0025	0.12	
	rs2016740	4	113238018	0.0039	0.17	
	rs719006	15	59210481	0.0044	0.76	RORA
	rs877936	4	113238472	0.0055	0.31	
	rs1436136	4	113421130	0.0062	0.039	
	rs1436336	3	106156256	0.0067	0.0040	
	rs698270	3	137592210	0.0086	0.020	STAG1
	rs847428	7	16803192	0.019	0.025	
	rs2359763	3	23424931	0.024	0.0025	
	rs7969455	12	7757402	0.059	0.0015	DPPA3
	rs10503717	8	22634817	0.06	0.0028	
	rs4899940	14	87623621	0.11	0.0019	
<b>3b. Combined phenotypes within a specific biological domain</b>						
C-reactive protein: exams 2, 5, 6, 7	rs2808629	1	156489869	6.9*10 <sup>-5</sup>	4.7*10 <sup>-4</sup>	NFIA, CRP
	rs2794520	1	156491889	6.1*10 <sup>-5</sup>	4.85*10 <sup>-4</sup>	FCER1A, CRP
	rs6563212	13	35380415	7.3*10 <sup>-4</sup>	0.30	DCAMK1
	rs11626844	14	72413330	5.1*10 <sup>-3</sup>	0.17	OR10J1, DPF3
	rs9319160	13	84918646	0.002	0.09	
	rs910232	1	17143820	0.002	0.01	MAG11, PAD12
Liver function: Alkaline phosphatase; AST; ALT; GGT	rs4911146	20	32103708	0.01	8.4*10 <sup>-6</sup>	ARL6IP6, RALY
	rs953402	3	5986639	0.01	9.1*10 <sup>-6</sup>	FMNL2
Vitamin D, Vitamin K phyloquinone & Vitamin K % undercarboxylated osteocalcin	rs1376544	4	180293700	0.02	9.2*10 <sup>-6</sup>	

Chr = chromosome;  
 For a given SNP, all of the phenotypes either FBAT or GEE significant if FBAT < 0.01 for particular SNP;  
 P-values = the geometric mean of the p-value for all traits within the biomarker cluster

nificant SNPs for FBAT were the same two SNPs observed with GEE: MCP1 concentrations were significantly associated with rs4128725,  $p = 3.28 \times 10^{-8}$ , and rs2494250,  $p = 3.55 \times 10^{-8}$  (Table 2b). In addition, B-type natriuretic peptide (rs437021,  $p = 1.01 \times 10^{-6}$ ) and Vitamin K% undercarboxylated osteocalcin (rs2052028,  $p = 1.07 \times 10^{-6}$ ) also were nominally statistically significantly associated.

In Table 2c we list the magnitude and location of LOD scores > 2.5 observed for the circulating biomarker traits. Because we were concerned that some of the LOD scores might be inflated by individuals with extreme marker concentrations, we reanalyzed the LOD scores on Winsorized residuals. The peak Winsorized LOD scores observed were for the biomarkers MCP1 (4.38, chromosome 1), and CRP (3.23, chromosome 10; 3.28, chromosome 1). Of note the 1.5 LOD support intervals for the linkage peaks on chromosome 1 included the SNPs significantly associated with MCP1 and CRP reported above (GEE model).

In an effort to potentially uncover genetic pleiotropy we display in Table 3 two ways to synthesize findings across phenotypes. We examined 3 correlated inflammatory biomarker phenotypes, interleukin-6, CRP and fibrinogen, and report SNPs that were significantly associated with all 3 phenotypes by GEE or FBAT at  $p < 0.01$  (Table 3a). We also examined phenotypes within a specific biomarker category including CRP over multiple examinations, liver function tests and vitamin concentrations (nutrients involved in bone health [37,38]), and display in Table 3b SNPs significant by either FBAT or GEE at a  $p < 0.01$  for all of the phenotypes in a given phenotype cluster.

In Table 4 we compared our data with previously reported phenotype-genotype associations in the published literature on systemic biomarker concentrations: bilirubin concentrations (TA repeat in *UGT1A1*) [39,40]; CRP (*CRP*) [20,32,41-50], intercellular adhesion molecule-1 (*ICAM1*) [51-54], interleukin-6 (*IL6*) [55-62], and MCP1

(*CCL2* = *MCP1* gene [63,64]). Unfortunately, there were no SNPs within 60 KB of the *ICAM1* gene on the Affymetrix 100K chip. There was no association between bilirubin concentrations and 1 SNP within 30 kb (rs741159) + 2 more SNPs within 50 kb (rs726017 and rs6752792) of a previously reported TA repeat in *UGT1A1*. Additionally, there was no association between interleukin-6 concentrations and SNPs in the *IL6* region despite one SNP in high LD (linkage disequilibrium;  $r^2 = 0.819$ ) with the previously reported rs1800795 (-174G/C) SNP. Similarly, we did not observe an association between *MCP1* concentrations and SNPs in the *CCL2* region, despite one SNP with a high  $r^2$  (0.956) with the SNP previously reported in the literature. For CRP concentrations, we had 2 SNPs in perfect LD with rs1205, and we observed strong evidence for replication. However, it should be noted that this association has been previously reported by Framingham investigators in unrelated participants [32]. Similarly, rs431568, which is in high LD ( $r^2 = 0.83$ ) with 2 previously associated SNPs (rs3116653 and rs1417938), was highly associated with many of the CRP phenotypes.

## Discussion

In collaboration with NCBI we have web-posted our unfiltered biomarker-genotype associations and linkage results to provide a resource to investigators seeking to understand and replicate their biomarker-genotype associations. We submit that the findings of highest priority for follow-up are associations that were detected by several statistical approaches. *MCP1* was associated with 2 SNPs on chromosome 1 (rs4128725 and rs2494250) with  $p$ -values in the  $10^{-8}$  by FBAT,  $\leq 10^{-12}$  by GEE. Acknowledging that linkage is less powerful and accurate, we note that the 1.5 support interval for the *MCP1* linkage peak (Winsorized maximum LOD 4.38) on chromosome 1 supports the GEE and FBAT analyses. Findings for CRP (chromosome 1), brain natriuretic peptide (chromosome 1) and Vitamin K % undercarboxylated osteocalcin (Chromosome 7) are also of potential priority for follow-up. We acknowledge that the ultimate validation of our findings will require replication in other cohorts and functional studies.

A fundamental challenge of GWAS tests is sorting through associations and prioritizing SNPs for follow-up. In the absence of external replication, one approach to synthesizing findings is to examine associations across similar biological domains, which may capture pleiotropy. We presented the exploratory analyses in Tables 3a and 3b, but reiterate that the findings will need to be examined in other cohorts.

## Do the findings represent true positive genetic associations?

It is notable that some of the associations with the strongest statistical support were for associations between a gene and its protein product (e.g. *CRP* gene and CRP concentration). Cis-acting regulatory variants have been shown to influence mRNA and protein levels for many genes [65]. Studies involving additional biomarker phenotypes and variants (e.g. Affymetrix 500 K Chip) should clarify whether cis- or trans-acting regulatory variants explain the greatest proportion of phenotypic variation.

With GWAS, which typically test for the association of 1000s of SNPs with multiple traits, it is difficult for any specific association to achieve genome wide significance. For instance, a strict Bonferroni correction for the 30 traits tested in the present study with both age/sex- and multi-variable-adjusted models and 2 statistical methods ( $0.05 / (70,987 * 30 * 2 * 2)$ ) would require a  $p = 5.9 \times 10^{-9}$ . We submit that the most significant association in the selected biomarker group, the *FCER1A* rs2494250 SNP with *MCP1* concentrations achieved genome-wide significance with a GEE  $p = 1.0 * 10^{-14}$  and a FBAT  $p = 3.5 * 10^{-8}$ . It should be noted that rs2494250 and rs4128725 are in modest linkage disequilibrium ( $D' = 0.724$  and  $r$  squared = 0.196) and hence, may be serving as proxies for the same causal SNP.

Several human and experimental studies suggest that the association between *FCER1A* and *MCP1* concentrations is biologically plausible. *FCER1A* codes for the high affinity Fc receptor fragment for IgE. In vitro experiments with rat mast cells demonstrated that if aggregated the high affinity receptor for IgE (FcεRI) increased gene transcription and secretion of *MCP1* [66]. Similarly, in mice mast cells if the FcεRI was occupied by small amounts IgE/antigen, *MCP1* mRNA increased significantly [67]. In humans IgE and *MCP1* concentrations are both increased in occupational asthma [68,69]. Similar to the animal data, human mast cells exposed to anti-IgE antibody or to IgE released *MCP1* [70-72].

## Comparison with prior literature

Our efforts to compare our findings with associations previously reported in the literature underscore some of the challenges in genetic association studies. The *ICAM1* gene did not have any markers within 60 kb on the Affymetrix 100K chip. Of the 4 genes that did have SNPs in the marker genomic region coding, only the *CRP* association was replicated in our cohort; however as noted above we [32], as well as others [20], have previously reported this association. For bilirubin concentrations we previously reported significant linkage to chromosome 2q telomere [39] and a significant association to a TA repeat in *UGT1A1*, under this linkage peak [40] in Framingham



**Table 4: Comparison with the prior literature**

Gene	rs number previous reports	# Affy SNPs within 60 kb	rs ID Affy SNPs	Chr	D'	r2	Distance Associated SNP	MAF	FBAT p-value	GEE p-value			
<b>IL6</b>	rs1800795 = -174G/C	7	rs6461667	7	1	0.82	30098	0.36	0.09	0.66			
<b>MCP1</b>	rs1024611	13	rs10491109	17	1	0.04	30762	0.15	0.048	0.13			
			rs1080327		1	0.96	11878	0.25	0.78	0.35			
			rs1860181			0.92	0.27	37799	0.45	0.04	0.11		
			rs1860182			0.92	0.27	37649	0.45	0.046	0.11		
<b>CRP average 2,6,7</b>	rs1205	37	rs3815341		1	0.02	34637	0.05	0.001	0.50			
			rs1446959	1	0.56	0.12	75429	0.39	0.86	0.002			
			rs1891187			0.39	0.05	53180	0.33	0.30	0.02		
			rs2808629	1	1	5437	0.34	4.8*10 <sup>-5</sup>	3.2*10 <sup>-8</sup>				
			rs2794520	1	1	3417	0.34	4.3*10 <sup>-5</sup>	2.8*10 <sup>-8</sup>				
			rs4131568			0.63	0.12	39823	0.30	0.004	0.001		
			rs1446959			0.5	0.16	77382	0.39	0.86	0.002		
			rs1891187			0.29	0.07	55133	0.33	0.30	0.02		
			rs2808629	1	0.25	7390	0.34	4.8*10 <sup>-5</sup>	3.2*10 <sup>-8</sup>				
			rs2794520	1	0.25	5370	0.34	4.3*10 <sup>-5</sup>	2.8*10 <sup>-8</sup>				
			rs4131568	1	0.83	37870	0.30	0.004	0.001				
			rs1446959			0.66	0.03	72832	0.39	0.86	0.002		
			rs3093077			rs1891187		0.47	0.02	50583	0.33	0.30	0.02
						rs2808629	1	0.03	2840	0.34	4.8*10 <sup>-5</sup>	3.2*10 <sup>-8</sup>	
						rs2794520	1	0.03	820	0.34	4.3*10 <sup>-5</sup>	2.8*10 <sup>-8</sup>	
						rs4131568	1	0.03	42420	0.30	0.004	0.001	
			rs1446959		0.51	0.17	90106	0.39	0.86	0.002			
rs3116653			rs1891187		0.31	0.08	67857	0.33	0.30	0.02			
			rs2808629	1	0.25	20114	0.34	4.8*10 <sup>-5</sup>	3.2*10 <sup>-8</sup>				
			rs2794520	1	0.25	18094	0.34	4.3*10 <sup>-5</sup>	2.8*10 <sup>-8</sup>				
			rs4131568	1	0.83	25146	0.30	0.004	0.001				

Displayed are SNPs that are either in the highest LD ( $r^2$ ) with previously reported SNPs or that have an FBAT or GEE p-value < 0.05. For bilirubin concentrations in Framingham study unrelated participants we previously reported significant linkage to chromosome 2q telomere [39] and a significant association to a TA repeat *UGT1A1*, there were no association between bilirubin concentrations and 1 SNP within 30 kb (rs741159) + 2 more SNPs within 50 kb (rs726017 and rs6752792). The previously reported *UGT1A1* variant is not a SNP and therefore not in HapMap; we have no LD information and cannot assess whether the association previously reported is also present in the current sample. *ICAMI* on chromosome 19 has 3 reported SNPs in literature (rs1799969, rs5491, rs5498), but there were no Affymetrix SNPs within 60 KB of the gene. **CCL2** [Other associated SNPs: rs2857654, rs1024610, rs2857657 are NOT in HapMap, so no LD information was available. **CRP** 2 SNPs are in perfect LD with rs1205. The previously reported triallelic SNP rs3091244 is not in HapMap. CRP association was previously reported in Framingham unrelated participants [32].

unrelated participants. However, there was no association between bilirubin concentrations and the 3 SNP within 60 kb of *UGT1A1*. The previously reported interleukin-6-*IL6* and the MCP1-*CCL2* associations were not replicated. Of note, our group previously reported that rs1024611 [in *CCL2*] was associated with MCP1 concentrations in unrelated participants [63]; the association was nowhere close to significant in the present report (FBAT p = 0.78; GEE p = 0.35) Possible explanations of the failure to confirm the previously reported Framingham study MCP1-*CCL2* association may stem from the current report having a smaller sample size (n = 989), using different genetic markers, and being conducted with an additive genetic model in related participants, as opposed to the prior study using unrelated participants (n = 1602) with recessive and dominant models. In a recent meta-analysis of phenotype-genotype association studies, only about one third (8 of 25) of the associations examined were replicated [73]. There are many plausible explanations why we did not replicate previously reported phenotype-genotype associations. Previous reports could represent false positive findings, or the present and prior study cohorts may differ on key fac-

tors, which may modify the phenotype-genotype associations, or our lack of replication may represent a false negative report because of inadequate statistical power [73,74].

**Strengths and limitations**

The strengths of the present study include a comprehensively characterized community-based cohort, with biomarker phenotypes routinely assessed with careful attention to quality control. However, the cohort was largely middle-aged to elderly, and white of European descent, so the findings may not be generalizable to individuals who are younger or of other ethnicity/racial descent. DNA was collected at the 5<sup>th</sup> and 6<sup>th</sup> examinations, which may have introduced a survival bias. In addition, our study was susceptible to false negative findings because of the moderate size of the cohort; we lacked power to detect modest associations. Conversely, similar to most GWAS, the reported associations and linkage may represent false positive findings from multiple statistical testing.

## Conclusions and future directions

The Framingham GWAS and the web posting of the unfiltered results represent a unique resource to discover potentially novel genetic influences on systemic biomarker variability. We acknowledge that the newly described associations will need to be replicated in other studies.

## Abbreviations

bp, base pair; Chr, chromosome; CRP, C-reactive protein; FBAT, Family Based Association Tests; GEE, Generalized Estimating Equations; GWAS, Genome-wide association studies; LD, linkage disequilibrium; LOD, logarithm of the odds (base 10); MCP-1, monocyte chemoattractant protein-1; SNPs, single nucleotide polymorphisms.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

EJB conceived of the FHS inflammation project, secured funding, planned the analyses, drafted and critically revised the manuscript. JD assisted in planning and conducting the analyses, and in writing and critically revising the manuscript. MGL planned the FHS inflammation project including assisting in securing funding, and planned and conducted analyses. KLL assisted in planning and conducting the analyses. SLB measured the vitamin data, assisted in planning the analyses and critically revising the manuscript. DRG participated in the study design and reviewed the manuscript. SK contributed to analyses of C-reactive protein and osteoprotegerin, and reviewed the manuscript. JFK assisted in securing the funding, supervised and organized the performance of the assays and reviewed the manuscript. MJK contributed to collecting the data base and revising the manuscript. JPL provided insights into the liver function test analyses and reviewed and approved the manuscript. JBM secured funding for and oversaw measurement of high-sensitivity TNF $\alpha$  concentrations and reviewed and approved the manuscript. SJR contributed to acquisition of the inflammation data, reviewing, revising and giving final approval to the manuscript. JR provided critical assistance in organizing the inflammatory marker data set, conducted quality control analyses and reviewed and gave final approval to the manuscript. RS was involved in revising the manuscript critically for important intellectual content and gave final approval of the version to be published. JAV assisted in securing funding for the inflammation project and revising the manuscript. TJW contributed to the analysis and interpretation of the data, and revision of the manuscript for important intellectual content. PFW contributed to data acquisition, revision of the manuscript and final approval of the version submitted. PAW participated in 100K study design and reviewed and approved the manuscript. RSV provided critical input in conceiving the

project, securing the funding, planning the analyses and critically revising the manuscript.

## Acknowledgements

The investigators would like to express their gratitude to the Framingham Heart Study participants and key collaborators: Fox CS, Jacques PF, Lee DS, Lipinska I, Massaro JM, Murabito JM, O'Donnell CJ, Seshadri S, Yang Q. The core examinations were funded by N01-HC25195. A portion of the research was conducted using the Boston University Linux Cluster for Genetic Analysis (LinGA) funded by the NIH NCRR (National Center for Research Resources) Shared Instrumentation grant (1S10RR163736-01A1). Inflammatory markers were measured via HL064753, HL076784, AG028321 (EJB), HL71039 (RSV) and 2 K24HL04334 (RSV); osteoprotegerin work was supported by HL064753, HL076784, AG028321 (EJB) and the Doris Duke Charitable Foundation and NIH IK23 HL083102 (SK). TNF-alpha concentrations were measured via American Diabetes Association Career Development Award and NCRR GCRC M01-RR-01066 (JBM); Natriuretic peptides were measured by Shionogi & Co., Ltd. with an unrestricted research grant; Liver function tests were funded by the core contract; Vitamins were measured by federal funds from the U.S. Department of Agriculture, Agricultural Research Service under Cooperative Agreement No. 58-1950-001 and No. 58-1950-4-401, National Institute of Aging (AG14759).

This article has been published as part of *BMC Medical Genetics* Volume 8 Supplement 1, 2007: The Framingham Heart Study 100,000 single nucleotide polymorphisms resource. The full contents of the supplement are available online at <http://www.biomedcentral.com/1471-2350/8?issue=S1>.

## References

1. Vasan RS: **Biomarkers of cardiovascular disease: molecular basis and practical considerations.** *Circulation* 2006, **113**:2335-2362.
2. Nabel EG: **Genomic medicine and cardiovascular disease. Simon Dack Lecture. The American College of Cardiology.** [[http://www.nhlbi.nih.gov/directorspage/pageimages/03-11-06-acc\\_dack\\_nabel.pdf](http://www.nhlbi.nih.gov/directorspage/pageimages/03-11-06-acc_dack_nabel.pdf)]. 3-11-2006.
3. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, Rupprecht HJ, Bickel C, Tiret L, Cambien F, Gerstein H, Munzel T, Yusuf S: **Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.** *Circulation* 2006, **114**:201-208.
4. Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P: **N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults.** *JAMA* 2005, **293**:1609-1616.
5. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS: **Plasma natriuretic peptide levels and the risk of cardiovascular events and death.** *N Engl J Med* 2004, **350**:655-663.
6. Wannamethee G, Ebrahim S, Shaper AG: **Gamma-glutamyltransferase: determinants and association with mortality from ischemic heart disease and all causes.** *Am J Epidemiol* 1995, **142**:699-708.
7. Lee DS, Evans JC, Robins SJ, Wilson PW, Albano I, Fox CS, Wang TJ, Benjamin EJ, D'Agostino RB, Vasan RS: **Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study.** *Arterioscler Thromb Vasc Biol* 2007, **27**:127-133.
8. Scragg R, Jackson R, Holdaway IM, Lim T, Beaglehole R: **Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study.** *Int J Epidemiol* 1990, **19**:559-563.
9. Ridker PM, Hennekens CH, Buring JE, Rifai N: **C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.** *N Engl J Med* 2000, **342**:836-843.

10. Danesh J, Collins R, Appleby P, Peto R: **Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies.** *JAMA* 1998, **279**:1477-1482.
11. Kuller LH, Tracy RP, Shaten J, Meilahn EN, the MRFIT Research Group: **Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study.** *Am J Epidemiol* 1996, **144**:537-547.
12. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J: **Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men.** *Lancet* 1998, **351**:88-92.
13. Harris TB, Ferrucci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, Heimovitz H, Cohen HJ, Wallace R: **Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly.** *Am J Med* 1999, **106**:506-512.
14. Dupuis J, Larson MG, Vasani RS, Massaro JM, Wilson PW, Lipinska I, Corey D, Vita JA, Keaney JF Jr, Benjamin EJ: **Genome scan of systemic biomarkers of vascular inflammation in the Framingham Heart Study: evidence for susceptibility loci on 1q.** *Atherosclerosis* 2005, **182**:307-314.
15. Pankow JS, Folsom AR, Cushman M, Borecki IB, Hopkins PN, Eckfeldt JH, Tracy RP: **Familial and genetic determinants of systemic markers of inflammation: the NHLBI family heart study.** *Atherosclerosis* 2001, **154**:681-689.
16. Wang TJ, Larson MG, Levy D, Benjamin EJ, Corey D, Leip EP, Vasani RS: **Heritability and genetic linkage of plasma natriuretic peptide levels.** *Circulation* 2003, **108**:13-16.
17. Bathum L, Petersen HC, Rosholm JU, Hyltoft PP, Vaupel J, Christensen K: **Evidence for a substantial genetic influence on biochemical liver function tests: results from a population-based Danish twin study.** *Clin Chem* 2001, **47**:81-87.
18. Pilia G, Chen WM, Scuteri A, Orru M, Albai G, Dei M, Lai S, Usala G, Lai M, Loi P, Mameli C, Vacca L, Deiana M, Olla N, Masala M, Cao A, Najjar SS, Terracciano A, Nedozov T, Sharov A, Zonderman AB, Abecasis GR, Costa P, Lakatta E, Schlessinger D: **Heritability of cardiovascular and personality traits in 6,148 Sardinians.** *PLoS Genet* 2006, **2**:e132.
19. Hunter D, De Lange M, Snieder H, MacGregor AJ, Swaminathan R, Thakker RV, Spector TD: **Genetic contribution to bone metabolism, calcium excretion, and vitamin D and parathyroid hormone regulation.** *J Bone Miner Res* 2001, **16**:371-378.
20. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M, Liu K, Williams OD, Iribarren C, Lewis EC, Fornage M, Boerwinkle E, Gross M, Jaquish C, Nickerson DA, Myers RM, Siscovick DS, Reiner AP: **Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels.** *Am J Hum Genet* 2005, **77**:64-77.
21. Cupples LA, Arruda HT, Benjamin EJ, D'Agostino RB Sr, Demissie S, DeStefano AL, Dupuis J, Falls K, Fox CS, Gottlieb DJ, Govindaraju DR, Guo CY, Heard-Costa NL, Hwang SJ, Kathiresan S, Kiel DP, Laramie JM, Larson MG, Levy D, Liu CY, Lunetta KL, Mailman MD, Manning AK, Meigs JB, Murabito JM, Newton-Cheh C, O'Connor GT, O'Donnell CJ, Pandey MA, Seshadri S, Vasani RS, Wang ZY, Wilk JB, Wolf PA, Yang Q, Atwood LD: **The Framingham Heart Study 100K SNP genome-wide association study resource: Overview of 17 phenotype working group reports.** *BMC Med Genet* 2007, **8**(Suppl 1):S1.
22. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP: **An investigation of coronary heart disease in families. The Framingham offspring study.** *Am J Epidemiol* 1979, **110**:281-290.
23. Vasani RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D: **Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study.** *JAMA* 2002, **288**:1252-1259.
24. Walters MI, Gerarde HW: **A microspectrophotometric method for the determination of bilirubin.** *Microchemical J* 1968, **13**:253-272.
25. Djousse L, Levy D, Cupples LA, Evans JC, D'Agostino RB, Ellison RC: **Total serum bilirubin and risk of cardiovascular disease in the Framingham offspring study.** *Am J Cardiol* 2001, **87**:1196-1200.
26. Roy AV: **Rapid method for determining alkaline phosphatase activity in serum with thymolphthalein monophosphate.** *Clin Chem* 1970, **16**:431-436.
27. Proksch GJ, Bonderman DP, Griep JA: **AutoAnalyzer assay for serum alkaline phosphatase activity, with sodium thymolphthalein monophosphate as substrate.** *Clin Chem* 1973, **19**:103-105.
28. Henry RJ, Chiamori N, Golub OJ, Berkman S: **Revised spectrophotometric methods for the determination of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, and lactic acid dehydrogenase.** *Am J Clin Pathol* 1960, **34**:381-398.
29. Davidson KW, Sadowski JA: **Determination of vitamin K compounds in plasma or serum by high-performance liquid chromatography using postcolumn chemical reduction and fluorimetric detection.** *Methods Enzymol* 1997, **282**:408-421.
30. Gundberg CM, Hauschka PV, Lian JB, Gallop PM: **Osteocalcin: isolation, characterization, and detection.** *Methods Enzymol* 1984, **107**:516-544.
31. Gundberg CM, Nieman SD, Abrams S, Rosen H: **Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin.** *J Clin Endocrinol Metab* 1998, **83**:3258-3266.
32. Kathiresan S, Larson MG, Vasani RS, Guo CY, Gona P, Keaney JF Jr, Wilson PW, Newton-Cheh C, Musone SL, Camargo AL, Drake JA, Levy D, O'Donnell CJ, Hirschhorn JN, Benjamin EJ: **Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level.** *Circulation* 2006, **113**:1415-1423.
33. Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeuffer A, Illig T, Wichmann HE, Meitinger T, Hunter D, Hu FB, Colditz G, Hinney A, Hebebrand J, Koberwitz K, Zhu X, Cooper R, Ardlie K, Lyon H, Hirschhorn JN, Laird NM, Lenburg ME, Lange C, Christman MF: **A common genetic variant is associated with adult and childhood obesity.** *Science* 2006, **312**:279-283.
34. Abecasis GR, Cherny SS, Cookson WO, Cardon LR: **Merlin - rapid analysis of dense genetic maps using sparse gene flow trees.** *Nat Genet* 2002, **30**:97-101.
35. Almasy L, Blangero J: **Multipoint quantitative-trait linkage analysis in general pedigrees.** *Am J Hum Genet* 1998, **62**:1198-1211.
36. Nagelkerke NJD: **A note on a general definition of the coefficient of determination.** *Biometrika* 1991, **78**:691-692.
37. Cockayne S, Adamson J, Lanham-New S, Shearer MJ, Gilbody S, Torgerson DJ: **Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials.** *Arch Intern Med* 2006, **166**:1256-1261.
38. Szulc P, Chapuy MC, Meunier PJ, Delmas PD: **Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women.** *J Clin Invest* 1993, **91**:1769-1774.
39. Lin JP, Cupples LA, Wilson PW, Heard-Costa N, O'Donnell CJ: **Evidence for a gene influencing serum bilirubin on chromosome 2q telomere: a genomewide scan in the Framingham study.** *Am J Hum Genet* 2003, **72**:1029-1034.
40. Lin JP, O'Donnell CJ, Schwaiger JP, Cupples LA, Lingenhel A, Hunt SC, Yang S, Kronenberg F: **Association between the UGT1A1\*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study.** *Circulation* 2006, **114**:1476-1481.
41. Zee RY, Ridker PM: **Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis.** *Atherosclerosis* 2002, **162**:217-219.
42. Szalai AJ, McCrory MA, Cooper GS, Wu J, Kimberly RP: **Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene.** *Genes Immun* 2002, **3**:14-19.
43. Suk HJ, Ridker PM, Cook NR, Zee RY: **Relation of polymorphism within the C-reactive protein gene and plasma CRP levels.** *Atherosclerosis* 2005, **178**:139-145.
44. Davey SG, Lawlor DA, Harbord R, Timpson N, Rumley A, Lowe GD, Day IN, Ebrahim S: **Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality.** *Arterioscler Thromb Vasc Biol* 2005, **25**:1051-1056.
45. Balistreri CR, Vasto S, Listi F, Grimaldi MP, Lio D, Colonna-Romano G, Caruso M, Caimi G, Hoffmann E, Caruso C, Candore G: **Association between +1059G/C CRP polymorphism and acute myocardial infarction in a cohort of patients from Sicily: a pilot study.** *Ann N Y Acad Sci* 2006, **1067**:276-281.
46. Miller DT, Zee RY, Suk DJ, Kozlowski P, Chasman DI, Lazarus R, Cook NR, Ridker PM, Kwiatkowski DJ: **Association of Common**

- CRP Gene Variants with CRP Levels and Cardiovascular Events.** *Ann Hum Genet* 2005, **69**:623-638.
47. Eklund C, Lehtimäki T, Hurme M: **Epistatic effect of C-reactive protein (CRP) single nucleotide polymorphism (SNP) +1059 and interleukin-1B SNP +3954 on CRP concentration in healthy male blood donors.** *Int J Immunogenet* 2005, **32**:229-232.
  48. Szalai AJ, Wu J, Lange EM, McCrory MA, Langefeld CD, Williams A, Zakharkin SO, George V, Allison DB, Cooper GS, Xie F, Fan Z, Edberg JC, Kimberly RP: **Single-nucleotide polymorphisms in the C-reactive protein (CRP) gene promoter that affect transcription factor binding, alter transcriptional activity, and associate with differences in baseline serum CRP level.** *J Mol Med* 2005, **83**:440-447.
  49. D'Aiuto F, Casas JP, Shah T, Humphries SE, Hingorani AD, Tonetti MS: **C-reactive protein (+1444C>T) polymorphism influences CRP response following a moderate inflammatory stimulus.** *Atherosclerosis* 2005, **179**:413-417.
  50. Kovacs A, Green F, Hansson LO, Lundman P, Samnegard A, Boquist S, Ericsson CG, Watkins H, Hamsten A, Tornvall P: **A novel common single nucleotide polymorphism in the promoter region of the C-reactive protein gene associated with the plasma concentration of C-reactive protein.** *Atherosclerosis* 2005, **178**:193-198.
  51. Register TC, Burdon KP, Lenchik L, Bowden DW, Hawkins GA, Nicklas BJ, Lohman K, Hsu FC, Langefeld CD, Carr JJ: **Variability of serum soluble intercellular adhesion molecule-1 measurements attributable to a common polymorphism.** *Clin Chem* 2004, **50**:2185-2187.
  52. Puthothu B, Krueger M, Bernhardt M, Heinzmann A: **ICAM1 amino acid variant K469E is associated with paediatric bronchial asthma and elevated sICAM1 levels.** *Genes Immun* 2006, **7**:322-326.
  53. Kronig H, Riedel M, Schwarz MJ, Strassnig M, Moller HJ, Ackenheil M, Muller N: **ICAM G241A polymorphism and soluble ICAM-1 serum levels: evidence for an active immune process in schizophrenia.** *Neuroimmunomodulation* 2005, **12**:54-59.
  54. Ponthieux A, Lambert D, Herbeth B, Drosch S, Pfister M, Visvikis S: **Association between Gly241Arg ICAM-1 gene polymorphism and serum sICAM-1 concentration in the Stanislas cohort.** *Eur J Hum Genet* 2003, **11**:679-686.
  55. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, Lowe GD, Humphries SE: **Interleukin-6 gene -174g>c and -572g>c promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery.** *Arterioscler Thromb Vasc Biol* 2001, **21**:1458-1463.
  56. Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Cantini F, Macchioni P, Bajocchi G, Catanoso MG, Pulsatelli L, Consonni D, Salvarani C: **Relationship between interleukin 6 promoter polymorphism at position -174, IL-6 serum levels, and the risk of relapse/recurrence in polymyalgia rheumatica.** *J Rheumatol* 2006, **33**:703-708.
  57. Liu Y, Berthier-Schaad Y, Fallin MD, Fink NE, Tracy RP, Klag MJ, Smith MW, Coresh J: **IL-6 haplotypes, inflammation, and risk for cardiovascular disease in a multiethnic dialysis cohort.** *J Am Soc Nephrol* 2006, **17**:863-870.
  58. Libra M, Signorelli SS, Bevelacqua Y, Navolanic PM, Bevelacqua V, Polesel J, Talamini R, Stivala F, Mazzarino MC, Malaponte G: **Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease.** *J Clin Pathol* 2006, **59**:211-215.
  59. Ravaglia G, Forti P, Maioli F, Chiappelli M, Dolzani P, Martelli M, Bianchin M, Mariani E, Bolondi L, Licastro F: **Associations of the -174 G/C interleukin-6 gene promoter polymorphism with serum interleukin 6 and mortality in the elderly.** *Biogerontology* 2005, **6**:415-423.
  60. Cardellini M, Perego L, D'Adamo M, Marini MA, Procopio C, Hribal ML, Andreozzi F, Frontoni S, Giacomelli M, Paganelli M, Pontiroli AE, Lauro R, Folli F, Sesti G: **C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance.** *Diabetes Care* 2005, **28**:2007-2012.
  61. Barbieri M, Rizzo MR, Papa M, Acampora R, De Angelis L, Olivieri F, Marchegiani F, Franceschi C, Paolisso G: **Role of interaction between variants in the PPARG and interleukin-6 genes on obesity related metabolic risk factors.** *Exp Gerontol* 2005, **40**:599-604.
  62. Haddy N, Sass C, Maumus S, Marie B, Drosch S, Siest G, Lambert D, Visvikis S: **Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort.** *Eur J Hum Genet* 2005, **13**:109-117.
  63. McDermott DH, Yang Q, Kathiresan S, Cupples LA, Massaro JM, Keane JF Jr, Larson MG, Vasan RS, Hirschhorn JN, O'Donnell CJ, Murphy PM, Benjamin EJ: **CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study.** *Circulation* 2005, **112**:1113-1120.
  64. Joven J, Coll B, Tous M, Ferre N, Alonso-Villaverde C, Parra S, Camps J: **The influence of HIV infection on the correlation between plasma concentrations of monocyte chemoattractant protein-1 and carotid atherosclerosis.** *Clin Chim Acta* 2006, **368**:114-119.
  65. Cheung VG, Spielman RS, Ewens KG, Weber TM, Morley M, Burdick JT: **Mapping determinants of human gene expression by regional and genome-wide association.** *Nature* 2005, **437**:1365-1369.
  66. Eglite S, Morin JM, Metzger H: **Synthesis and secretion of monocyte chemoattractant protein-1 stimulated by the high affinity receptor for IgE.** *J Immunol* 2003, **170**:2680-2687.
  67. Gonzalez-Espinosa C, Odom S, Olivera A, Hobson JP, Martinez ME, Oliveira-Dos-Santos A, Barra L, Spiegel S, Penninger JM, Rivera J: **Preferential signaling and induction of allergy-promoting lymphokines upon weak stimulation of the high affinity IgE receptor on mast cells.** *J Exp Med* 2003, **197**:1453-1465.
  68. Malo JL, L'Archeveque J, Lummus Z, Bernstein D: **Changes in specific IgE and IgG and monocyte chemoattractant protein-1 in workers with occupational asthma caused by diisocyanates and removed from exposure.** *J Allergy Clin Immunol* 2006, **118**:530-533.
  69. Bernstein DI, Cartier A, Cote J, Malo JL, Boulet LP, Wanner M, Milot J, L'Archeveque J, Trudeau C, Lummus Z: **Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has greater test efficiency than specific antibodies for identification of diisocyanate asthma.** *Am J Respir Crit Care Med* 2002, **166**:445-450.
  70. Baghestanian M, Hofbauer R, Kiener HP, Bankl HC, Wimazal F, Willheim M, Scheiner O, Fureder W, Muller MR, Bevec D, Lechner K, Valent P: **The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-1 in human lung mast cells.** *Blood* 1997, **90**:4438-4449.
  71. Matsuda K, Piliponsky AM, Iikura M, Nakae S, Wang EW, Dutta SM, Kawakami T, Tsai M, Galli SJ: **Monomeric IgE enhances human mast cell chemokine production: IL-4 augments and dexamethasone suppresses the response.** *J Allergy Clin Immunol* 2005, **116**:1357-1363.
  72. Gosset P, Tillie-Leblond I, Oudin S, Parmentier O, Wallaert B, Joseph M, Tonnel AB: **Production of chemokines and proinflammatory and antiinflammatory cytokines by human alveolar macrophages activated by IgE receptors.** *J Allergy Clin Immunol* 1999, **103**:289-297.
  73. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN: **Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease.** *Nat Genet* 2003, **33**:177-182.
  74. Hegele RA: **SNP judgments and freedom of association.** *Arterioscler Thromb Vasc Biol* 2002, **22**:1058-1061.